Research Projects

2014-2018

            Inflammatory bio-markers in Diabetes Mellitus - can they predict micro-vascular complications.


2014-2017

            Development of a simple method to detect Malarial parasite in vitro from whole blood.


2013-2016

            In silico modelling of auto immune diseases.


2007-2015

            Measures in Rheumatoid Arthritis (RA).


2006-2014

            Remission in Rheumatoid Arthritis - A prospective observational study.

            Antiphospholipid Antibody Syndrome (APS) – The outcome of pregnancies in women with antiphospholipid antibody positive.


2006-2015

            Relationship between stressful life events and onset of Rheumatoid Arthritis.


2004-2007

            Incidence of ocular findings in rheumatological disease.

            Anti nuclear antibody (ANA) profile and clinical feature correlation.

            Polymyositis and dermatomyositis clinical features and treatment.

            Co-morbid condition in psoriatic arthritis and other arthropathies.

 

Fellowship & Training projects for Post MD candidates
 

2014-2015 (On-going)

Dr. Mukhtar Ahmad Masoodi

Cross sectional observational study to establish the relationship between neutrophil to lymphocute ratio (NLR), Disease Activity Score (DAS), Health Assessment Questionnaire (HAQ) and Short Form 36 (SF36) in patients of Rheumatoid Arthritis.
 

2014-2015 (On-going)

Dr. Ashwini Kamath

To evaluate the role of neutrophil lymphocyte ratio, T-cell B-cell ratio and Th17/Treg ratio as potential markers predicting stable remission or low disease activity (LDA) in patients with Rheumatoid Arthritis in remission – An observational longitudinal study.

 

2014-2015

Dr. Sachin V. Dhote

To study the serum levels of homocysteine, uric acid, lipid profile and apo-lipoprotein A as biomarkers of metabolic stress of inflammation in recently diagnosed cases of rheumatoid arthritis, systemic lupus erythematosus, seronegative spondyloarthropathy and vasculitis.

 

2013-2014

Dr. Anand R. Patted

Estimation of total serum Vitamin D levels in rheumatoid arthritis and Vitamin D supplementation in deficiency state and evaluation of its relationship to the change in disease activity – Random consent screening, open label and interventional study.

 

2013-2014

Dr. Ranjit Mohan

Monitoring of disease activity in rheumatoid arthritis – A retrospective observational study to evaluate the efficacy of a new questionnaire and the derived scoring system as an instrument to monitor disease activity in rheumatoid arthritis in the intervals between clinical reviews.

 

2013-2014

Dr. Utkarsha Narone

Is early response of rheumatoid arthritis to any DMARD a good predictor of clinical outcome at one year – A retrospective study.

 

2010-2011

Dr. M.S. Arun

 Pressure pain threshold – A measure of disease activity of rheumatoid arthritis.

 

2009-2010

Dr, Apurva Khare

Role of psychological stress as a triggering factor for ankylosing spondylitis: A case control study.

 

Clinical Trial Projects

S.NO

Clinical Trial Projects Title

Year

Study Period

Recruitment Status

Study On

1

A Multicenter, Randomized, Double – Blind, Placebo controlled trials of Golimumab, a Fully Human Anti-TNF a Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve subjects with Active Rheumatoid Arthritis

2006 ONGOING

5 Year

CLOSED

RA

2

A Randomized, Open label, Four Arms Parallel Study to Evaluate the Safety and Efficacy of anti-CD6 monoclonal antibody (T1hMAb) in Combination with B9
CTRI No.and Date CTRI/2008/091/000295, 22-12-2008
UTRN.WHO TEMP UTRN 110159200-19122008397753

2006 COMPLETED

1 Year

CLOSED

RA

3

Double-blind, triple dummy, parallel-group, randomized, six month study to compare Celecoxib (200 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subjects with osteoarthritis and rheumatoid arthritis at high-risk of gastrointestinal adverse events. Protocol A3191084" from the sponsor company Pfizer Limited.

2007 COMPLETED

6 Months

CLOSED

RA

4

A phase II, randomized, double-blind, placebo-controlled, Parallel- group study to assess the safety and efficacy of Maraviroc (uk-427,857) in the treatment of rheumatoid Arthritis in subjects receiving Methotrexate for protocol No A4001056

2006 COMPLETED

2 YEARS

CLOSED

RA

5

A Phase IIIB, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to compare the efficacy and safety of Abatacept administered Subcutaneously and Intravenously in subjects with Rheumatoid Arthritis, receiving background Methotrexate, and experiencing an Inadequate response to Methotrexate.

2006 ONGOING

3 YEARS

CLOSED

RA

6

A Multicenter, randomized, double blind, placebo controlled study, comparing the efficacy and safety of BioCell Collagen II ® 1000 mg twice daily as compared with glucosamine sulfate 750 mg twice daily, biofermented hyaluronic acid 100 mg twice daily, glucosamine HCL 750 mg + chondroitin sulfate 600 mg twice daily and placebo twice daily in subjects with osteoarthritis.

2008 ONGOING

3 YEARS

CLOSED

RA

7

Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80mg, 160mg, and 320mg ALD518 versus Placebo Administered as Multiple Intravenous Infusions to Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate – ALD518-CLIN-003.

2007 COMPLETED

3 YEARS

CLOSED

RA

8

A Multi-Center, Randomized, Double -Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Uprate Lowering Therapy.

2008 ONGOING

3 YEARS

CLOSED

RA

9

A Multi-Center, Randomized, Double -Blind, Placebo Controlled Trial of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy.

2008 ONGOING

3 YEARS

CLOSED

RA

10

Study Title: An open label, non-comparative study to evaluate the efficacy, safety, and tolerability of Lornoxicam 8 mg tablet in the treatment of Rheumatoid Arthritis. 
CTRI No.and Date CTRI/2009/091/000297, 24-07-2009 UTRN.WHO TEMP UTRN 030232938-200520097411059

2009 ONGOING

3 YEARS

CLOSED

RA

11

Multi-National Open-Label Study to Evaluate the safety, Tolerability and efficacy of Tocilizumab in patients with Active Rheumatoid Arthritis on background Non-biologic DMARDs who have an Inadequate Response to current Non-biologic DMARD and/or Anti TNF Therapy

2009 COMPLETED

3 YEARS

CLOSED

RA

12

A Phase IIA, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012When Given with Methotrexate to Subjects With Active Rheumatoid Arthritis who have had an Inadequate response to Conventional Disease Modifying Anti-rheumatic drug therapy CTRI/2009/091/000642, 27-08-2009 TEMP UTRN 102429886-120820091108970

2008 COMPLETED

3 YEARS

CLOSED

RA

13

A Phase III , Multi-center, randomized double blind, controlled study of the long term analgesic efficacy and safety of Tanezumab alone or in combination with non-steroidal anti-inflammatory drugs(NSAIDs)versus NSAIDs alone in patients with osteoarthritis of the knee or hip. CTRI/2009/091/000405, 25-06-2009 TEMP UTRN 064015006-190620098621180

2009 ONGOING

3 YEARS

CLOSED

RA

14

A multicenter, phase III, single arm, open label trial of the efficacy and safety of certolizumab pegol given subcutaneously as an adjunctive medication to methotrexate in the treatment of rheumatoid arthritis in Indian subjects who have an inadequate response to methotrexate

2007 COMPLETED

2 YEARS

CLOSED

RA

15

"Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP-690,550 in Patients with Active Rheumatoid Arthritis on Background Methotrexate UTRN.WHO TEMP UTRN 113817210-2807200910601180 CTRI No.and Date CTRI/2009/091/000596, 29-07-2009

2008 APPROVED

2 YEARS

CLOSED

RA

16

A Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821, (an Anti-IL-17Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy. CTRI/2009/091/000777, 11-01-2010 TEMP UTRN 114017134-1709200912531078.

2009 ONGOING

1 YEAR

CLOSED

RA

17

Long terms, open label, follow up study of CP690-550. A Moderately selective Janus-Kinase-3 inhibitor for treatment of Rheumatoid Arthritis.

2010 ONGOING

2 YEARS

CLOSED

RA

18

An Open label, prospective, non-comparative, multicentre study to assess the safety and efficacy of Etanarcept for injection 25mg in patients with moderate to severe active rheumatoid arthritis.

2009 ONGOING

6 MONTHS

CLOSED

RA

19

A Prospective Observational Study to Evaluate Long-Term Safety and Functional Status of Subjects with Rheumatoid Arthritis Previously Enrolled in Studies of CP-690,550".

2010 ONGOING

2 YEARS

ONGOING

RA

20

Cytokine in Tuberculosis and contacts can it predict the outcome?

2010 APPROVED

6 MONTHS

ONGOING

RA

21

A study to ascertain the population prevalance of Rheumatic diseases in Bangalore Urban area.

2010 APPROVED

6 MONTHS

ONGOING

RA

22

D4300C00002 : (OSKIRA-2): Multi-Centre, Randomised, Double Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs

2010 APPROVED

1 YEAR

ONGOING

RA

23

(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis

2010 APPROVED

1 YEAR

ONGOING

RA

24

NA22823 B: A phase II/III seamless, multicentre, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with Tocilizumab versus placebo in patients with ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are naive to TNF antagonist theraphy

2010 APPROVAL AWAITED

5 YEARS

ONGOING

RA

25

14V-MC-JADA A randomized, double-blind, placebo-controlled, dose-ranging , parallel-group, phase 2b study of LY 3009104 in patients with Active Rheumatoid Arthritis on background Methotrexate theraphy

2010 APPROVED

6 MONTHS

ONGOING

RA

26

An Open-label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-modifying Antirheumatic Drug (DMARD) Therapy in Biologic-naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2) CTRI No.and Date CTRI/2009/091/000883, 23-11-2010 UTRN.WHO TEMP UTRN 061615108-271020091367923

2010 APPROVED

1 YEAR

CLOSED

RA

27

GP13,-201"A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficicacy of GP13-201 and rituximab in patients with rheumatoid arthritis refractory or intolerant to standard DMARDs and one or two anti-TNF therapies"

IN THE PIPELINE 2010

1 YEAR

YET TO BE APPROVED

RA

 

 

List of publications

1.    Ballooning of femoral head in juvenile idiopathic arthritis, S Chandrashekara, CL Deepak,  Internet Journals Of Case Reports 1 (1),   2016

 

2.   Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study,

       S Chandrashekara, Vineeta Shobha, BG Dharmanand, Ramesh Jois, Sharath Kumar, Kurugodu M Mahendranath, Vikram Haridas, Shiva Prasad, Yogesh Singh, Manisha A, Daware, Anupama Swamy, R Subramanian, Srirama A Somashekar, Arun M, Shanthappa, KR Anupama,  International Journal of Rheumatic Diseases,  2016

 

3.   High IL-6 and low IL-15 levels mark the presence of TB infection: A preliminary study, S Chandrashekara, KR Anupama, A Sambarey, N Chandra,  Cytokine 81, 57-62,  2016

 

4.   Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study, Arvind Chopra, S Chandrashekara, Rajgopalan Iyer, Liza Rajasekhar, Naresh Shetty, Sarathchandra Mouli Veeravalli, Alakendu Ghosh, Mrugank Merchant, Jyotsna Oak, Vikram Londhey, Abhijit Barve, MS Ramakrishnan, Enrique Montero, Clinical rheumatology 35 (4), 1059-1064,  2016

 

5.   Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis

       S Chandrashekara, A Rajendran, AB Jaganath, R Krishnamurthy, Reumatismo 67 (3), 109-115,   2016

 

6.   Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: an exploratory study,  S Chandrashekara, A Patted,   International journal of rheumatic diseases,   2015

 

7.   Managing elderly patients with musculoskeletal disorders warrants a different approach, S Chandrashekara,  Internet Journal of Rheumatology and Clinical Immunology 3 (S1),   2015

 

8.   AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses, J Kay, A Chopra, S Chandrashekara, D Olakkengil, K Bhojani, G Bhatia, G Rathi, M Thomas, S Maroli, E Thomson, C Lassen, L Shneyer, M Wyand,    Annals of the Rheumatic Diseases 74 (Suppl 2), 1034-1034, 2015

 

9.   Editorial foreword: Internet journal of case reports, S Chandrashekara,   Internet Journals Of Case Reports 1 (1),   2015

 

10.   Life events influence the development of ankylosing spondylitis: A case-control study Apurva Khare, Chandrashekara S; Indian Journal of Rheumatology & Clinical Immunology ; DOI: 10.15305/ijrci/v3i1/99;   Vol 3, No 1 (2015)

 

11.   Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study Arvind Chopra, S. Chandrashekara, Rajgopalan Iyer, Liza Rajasekhar, Naresh Shetty, et al; Brief Report: Clinical Rheumatology; pp 1-6; First online: 07 June 2015

 

12.   Neutrophil-lymphocyte ratio may serve as an important predictive marker for sustained rheumatoid arthritis remission

        S. ChandrashekaraR. AnithaJ. AnithaK. Renuka; ChanRe Rheumatology and Immunology Centre and Research,Bangalore,India;  Indian Journal of Rheumatology; DOI: http://dx.doi.org/10.1016/j.injr.2014.10.051; November 2014, Volume 9, Supplement 1, pages S20-S21

 

13.   A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. EULAR 2014: Scientific Abstracts J. Kay, A. ChopraS. ChandrashekaraD.J. Olakkengil, et al;  Ann Rheum Dis 2014;73:64

 

14.   A phase 3, randomized, bouble-blind, active comparator study of the efficacy and safety of bBow015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses  Arvind ChopraJonathan KayMichael S. WyandS. ChandrashekaraAvy J. Olakkengil, et al; Indian Journal of Rheumatology > 2014 > 9 > Supplement 1 > S17

 

15.    Potential role of transforming growth factor β1 and interleukin-6 in elderly type 2 diabetes mellitus patients 

M.S. Roopakala, Mahesh Eshwarappa , C.R. Wilma Delphine Silvia , Pushpa Krishna , Vasanth Kumar , S. Chandrashekara and K.M. Prasanna Kumar; Al Am een J Med Sci 2014; 7(2):160-163 ; US National Library of Medicine enlisted journal ; ISSN 0974-1143

 

16.    The quantum on inflammation is the critical predictors of achieving remission or low disease activity in treatment naïve rheumatoid arthritis, U Narone, S Chandrashekara, Indian Journal of Rheumatology 9, S21

 

17.    Neutrophil-lymphocyte ratio may serve as an important predictive marker for sustained rheumatoid arthritis remission, S Chandrashekara, R Anitha, J Anitha, K Renuka, Indian Journal of Rheumatology 9, S20-S21

 

18.    C-reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis,  S Chandrashekara,  Internet Journal of Rheumatology and Clinical Immunology 2 (S1)

 

19.    Hyperlipidemia with polyarthritis: A case report, SV Dhote, S Chandrashekara, Internet Journal of Pathology and Laboratory Medicine 1 (1)

 

20.    Current studies of biomarkers for the early diagnosis of rheumatoid arthritis., S Chandrashekara, I Center, Degenerative Neurological & Neuromuscular Disease 4

 

21.    Quantification of inflammation: Needs and challenges, S Chandrashekara,  Internet Journal of Rheumatology and Clinical Immunology 2 (S1)

 

22.    Mixed effect frameworks in the analysis of longitudinal data, KR Anupama, S Chandrashekara, Internet Journal of Rheumatology and Clinical Immunology 2 (1)

 

23.    Variation in pressure pain threshold correlates with rheumatoid arthritis disease activity, not with the    inflammatory parameters,

       AS Madhanaghatta, S Chandrashekara, SP Kuralyanapalya, Internet Journal of Rheumatology and Clinical Immunology 2 (1)

 

24.    Potential role of transforming growth factor β1 and interleukin-6 in elderly type 2 diabetes mellitus  patients., MS Roopakala, M Eshwarappa, CRWD Silvia, P Krishna, V Kumar, ...,  Al Ameen Journal of Medical Sciences  7 (2)

 

25.    A phase 3, randomized, bouble-blind, active comparator study of the efficacy and safety of bBow015, a  biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses, A Chopra, J Kay, MS Wyand, S Chandrashekara, AJ Olakkengil, ..., Indian Journal of Rheumatology 9, S17

 

26.    In pursuit of a solution for Autoimmune Rheumatic diseases

       S Chandrashekara, Oration lecture delivered in the 29th Annual national Conference of IRA in Kolkata on  6th December 2013

 

27.    Observational studies: Are they significant in the current evidence-based trial era? S Chandrashekara, RN Misra. Internet Journal of Rheumatology and Clinical Immunology. 1 (S1). 2013.

 

28.    The relevance of observational studies in rheumatology and clinical immunology S Chandrashekara. Internet Journal of Rheumatology and Clinical Immunology 1 (S) 2013.

 

29.    Pathogenesis of antiphospholipid antibody syndrome needs further exploration. S Chandrashekara, R Misra. Internet Journal of Rheumatology and Clinical Immunology. 1 (1). 2013.

 

30.    An unusual presentation of Wegener's granulomatosis during pregnancy. VM Haridas, S Chandrashekara, BG Dharmanand. Internet Journal of Rheumatology and Clinical Immunology. 1 (1). 2013.

 

31.    Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers. S Chandrashekara, BU Priyanka. International Journal of Rheumatic Diseases. 2013.

 

32.    Presentation of Ewing's sarcoma as unilateral sacroiliitis. VM Haridas, S Chandrashekara, BG Dharmanand. Internet Journal of Rheumatology and Clinical Immunology. 1 (1). 2013.

 

33.    Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis. Expert opinion on drug metabolism & toxicology. S Chandrashekara. 1-13. 2013.

 

34.    Occurrence of disabling myopathy secondary to hypovitaminosis D S Chandrashekara, UC Narone. Internet Journal of Rheumatology and Clinical Immunology 1 (1) 2013

 

35.    Remission occurs still only in minority of Rheumatoid arthritis while a tight control is achievable in a routine clinical practice – A cross section study, S. Chandrashekara, B. U. Priyanka, Indian Journal of Rheumatology, Vol. 8, Issue 1, p3-7, Published in issue: March 2013

 

36.    Calcinosis around the joints of hands and arteries S Chandrashekara. Internet Journal of Rheumatology and Clinical Immunology 1 (1)

 

37.    Measures in rheumatoid arthritis: are we measuring too many parameters. Chandrashekara S, Sachin S. Int J Rheum Dis. 2012 Jun;15(3):239-48. doi: 10.1111/j.1756- 185X.2012.01754.x. PubMed PMID: 22709486.

 

38.    Serum levels of interleukin-13 and interferon-gamma from adult patients with asthma in Mysore. Cytokine. Davoodi P, Mahesh PA, Holla AD, Vijayakumar GS, Jayaraj BS, Chandrashekara S, Ramachandra NB. 2012 Jun 12. [Epub ahead of print] PubMed PMID: 22698804.

 

39.    Moderate Regular Exercises Reduce Inflammatoryre Sponse For Physical Stress. V. Ambarish. S. Chandrashekara. , K. P. Suresh Indian J Physiol Pharmacol 2012; 56(1):7–14.

 

40.    ESR or CRP, which inflammatory measure can accurately replace clinical measures in rheumatoid arthritis? S. Chandrashekara, P. Renuka, K.P. Suresh, Indian Journal of Rheumatology, 2012 Volume 7, Issue 2, Pages 69-73.

 

41.    Sample size estimation and power analysis for clinical research studies. Suresh K P, Chandrashekara S., J Hum Reprod Sci 2012; 5: 7-13.

 

42.    The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review, S. Chandrashekara, Indian Journal of Pharmacology 44 (6), 665, Nov-Dec 2012

 

43.    Complementary and alternative medicine in rheumatoid arthritis. Chandrashekara S., Chin J Integr Med. 2011 Oct;17(10):731-4. Review. PubMed PMID: 22101695.

 

44.    Can bronchial asthma be classified based on the immunological status? Roopakala Mysore Subrahmanyam, Chandrashekara Srikantaiah, Pushpa Krishna, Chickbllapur Rayappa Wilma Delphine Silvia, Sandeep Thirunavukkarasu, Kusuma Devi, Mohan Rao, and Vasantha Kumar. , Lung India. 2011 Apr-jun; 28(2): 110–113. doi: 10.4103/0970-2113.80323 PMCID: PMC3109832.

 

45.    Occurrence of rheumatoid factor, anticardiolipin antibody and antinu-clear antibody in healthy Indian adults (greater than expected in youngadults) Lingaraj Jayalakshmi 1, Chandrashekara S. 2 , H.B.Veeranna. , Biomedical Research 2011 Volume 22 Issue 3 339 Biomedical Research 2011; 22 (3): 339-343.

 

46.    Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis. Shashikumar NS, Shivamurthy MC, Chandrashekara S., Indian J Pharmacol. 2010 Dec;42(6):358-61. PubMed PMID: 21189905; PubMed Central PMCID: PMC2991692.

 

47.    Evaluation of serum immunoglobulin E levels in bronchial asthma. Sandeep T, Roopakala MS, Silvia CR, Chandrashekara S, Rao M. , Lung India. 2010 Jul;27(3):138-40. PubMed PMID: 20931031; PubMed Central PMCID: PMC2946714.

 

48.    Influence of yoga on mood states, distress, quality of life and immune outcomes in early stage breast cancer patients undergoing surgery. Raghavendra M Rao, HR Nagendra, Nagarathna Raghuram, C Vinay, S Chandrashekara, KS Gopinath, BS Srinath., Int J Yoga. 2008 Jan;1(1):11-20.

 

49.    Effects of yoga on natural killer cell count5s I nearly breast cancer patients undergoing conventional treatment. Comment to: recreational music-making modulates natural killer cell activity, cytokines, and mood states in corporate employees Rao RM, Telles S, Nagendra HR, Nagarathna R, Gopinath K, Srinath S, Chandrashekara.S, masatada Wachi. Masahiro Koyama, Masanori Utsuyama, Barry B. Bittman, Masanobu Kitagawa, Katsuiku Hirokawa, Med Sci Monit, 2007;13(2): CR57-70.

 

50.    Cytokine response to strenuous exercise in athletes and non-athletes—an adaptive response. Gokhale R, Chandrashekara.S, Vasanthakumar.KC., Cytokine. 2007 Nov;40(2):123-7.

 

51.    Effects of anxiety on TNF-alpha levels during psychological stress. Chandrashekara.S, Jayashree K, Veeranna HB, Vadiraj HS, Ramesh MN, Shobha A, Saravanan Y, Vikram YK. , J Psychosom Res. 2007 Jul;63(1):65-9.

 

52.    Is three selected parameters adequate to monitor rheumatoid arthritis? Chandrashekara S, Syed M, Swapna R , Clin Rheumatol. 2007 jun;26(6):911-4.

 

53.    Do baseline IL-6 levels predict post-operative morbidity after surgery (CABG) in cardiac patients? S C, Mahadevan C, Chandrashekara.S, Thomas N, Vasantaha Kumar KC, Shivanand NV, Yeragani VK. , J Card Surg. 2006 Sep-Oct;21(5):521-2.

 

54.    Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor- negative suspected rheumatoid arthritis: is it worthwhile to order the test? Panchagnula R, Rajiv SR, Prakash J, Chandrashekara S, Suresh KP, J Clin Rheumatol. 2006 Aug;12(4):172-5.

 

55.    A The incidence of Proteus mirabilis infection increases in patients on treatment but does not trigger disease activity. Chandrashekara S, Patil R, Vadiraja HS, Shobha, Clin Rheumatol. 2006 Jul;25(4):520-3. Epub 2005 Nov 3.

 

56.    Sporadic reactive arthritis in north india : lack of iga response S Chandrashekara, A Aggarwal , K N Prasad, Ramnath Misra, J Indian Rheumatol Assoc 2004 : 12 : 134 – 138N.S.

 

57.    Hearing loss in rheumatoid arthritis a prospective clinical study. Reddy E.Konappa, Chandra Kiran C, Krishanan Anita, Chandrashekara. S, Kumar P, Nalinesh K.M, Srinivas C.V. , Indian Journal of Otology, 2003 Vo. 9, December, P-33-36

 

58.    Proteus mirabilis and rheumatoid arthritis: no association with the disease. Chandrashekara S, Ramesh MN, Shobha A, Saravanan Y, Vadiraja HS, Navaneeth BV, Sandhya Belwadi MR., Clin Rheumatol. 2003 Oct;22(4-5):268-70.

 

59.    Congenital flexion deformity of the wrist owing to an anomalous insertion of the flexor carpi ulnaris: a case report. Sunil TM, Chandrashekara S. , J Hand Surg [Am]. 2003 Sep;28(5):866-70.

 

60.    Proteus mirabilis and rheumatoid arthritis: no association with the disease. Chandrashekara S, Ramesh MN, Shobha A, Saravanan Y, Vadiraja HS, Navaneeth BV, Sandhya Belwadi MR. , Clin Rheumatol. 2003 Sep;22(3):218-20.

 

61.    Prevalence of anticardiolipin antibodies in various thrombotic conditions: a hospital based study. Dr. Chandrashekara. S, Dr. Kirthi. R, Ms. Joyce Varghese. , JAPI 2003, Vol.51:

 

62.    The incidence of Proteus mirabilis infection increases in the patients on treatment than it triggering disease activity. Chandrashekara S, Navaneeth BV, Rajreddy Patil, and Vadiraja HS. , APLAR, 2002 - Dec, Bangkok, Thailand.

 

63.    Complementary and Alternative Drug Therapy in Arthritis. Chandrashekara S, Anilkumar T and Jamuna S. , JAPI 2002; 50: 225-7.

 

64.    Post Lumbar puncture Spinal Subarachnoid hematoma causing paraplegia. Krishna KN, Chandrashekara S and Pai BS. , Neurology India Sep 2001.

 

65.    Hyper IgM Syndrome – An Immunodeficiency Disorder. Murhy V, Vishwanath, Chandrashekara S, Nagashree, Hegde RK and Prashanth. , JK Science 2001; 3 (3): 129- 31.

 

66.    Autoantibodies in the diagnosis of neurological diseases. Chandrashekara S. , Annals of Indian Academy of Neurology, 2001, Vol 4.

 

67.    Complementary and Alternative Medicine, Vitamins and Anti-oxidants in RA. ICP Technical Report - Rheumatoid Arthritis. Chandrashekara S. , Ed. Siddharth Kumar Das. 2001; 81–83.

 

68.    Rheumatology Knowledge at Primary Care – A Survey Report. Chandrashekara S. , JIRA 2000; 8 (3): 94-96.

 

69.    Congenital infections. Latha V, Janaki V and Chandrashekara S., Perinatology 1999; 2: 49-50.

 

70.    Spondyloarthropathy - an overview. Chandrashekara S. , Newsletter: Karnataka Orthopaedic Association 1997; 3: 14-15.

 

71.    Rheumatoid Arthritis: A new strategy. Chandrashekara S. , Newsletter: Karnataka Orthopaedic Association 1997; 2: 9-11.

 

72.    Immuno Suppression in Ophthalmology practice. Chandrashekara S and Diwakar RB. , Chakshu 1997; 14 (3): 19-21.

 

73.    Immuno Suppressive Drugs in Eye disease. Chandrashekara S., Chakshu 1997; 14 (3): 20-22.

 

74.    Is undifferentiated spondyloarthropathy a forme fruste of reactive arthritis? Aggarwal A, Misra R, Chandrashekara S, Prasad KN, Dayal R and Ayyagiri A., Br J. Rheumatol 1997; 36: 1001- 4.

 

75.    Is undifferentiated spondyloarthropathy a forme fruste of reactive arthritis? Aggarwal A, Chandrashekara S, Dayal R and Misra RN. , APLAR, 1996, Melbourne, Australia.

 

76.    NSAIDs and DMARDs in Rheumatoid Arthritis. Chandrashekara S and Nithyanand S. , J Internal Medicine (INDIA) 1994; 8 (Suppl): 17-21.